Stomach cancer mystery: is a common bug to blame?
NCT ID NCT07233447
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 100 adults in Guadeloupe who have just been diagnosed with stomach cancer. Researchers want to find out how many of them also have an H. pylori infection, a bacteria linked to stomach cancer. By testing tissue and blood samples, they hope to learn more about the connection between this infection and cancer in this population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2025
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients living in Guadeloupe for more than 6 months, referred to the gastroenterology departments of the University Hospital of Guadeloupe (CHUG) and to the gastroenterology practice of Dr. Durand, with an endoscopic diagnosis of gastric cancer confirmed by histopathological examination in one of the three endoscopy centers (CHUG, Polyclinique de la Guadeloupe, and Clinique des Eaux Claires), will be invited to participate in the study following their disclosure consultation.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient over 18 years of age residing in Guadeloupe for more than 6 months and with a primary diagnosis of gastric cancer * Patient having read the information note and having signed the consent to participate in the study * Patient with social security coverage. Exclusion Criteria: * Refusal to participate. * Patient who could not answer the questionnaires * Patient not affiliated to a social security scheme * Patient under legal protection (judicial safeguard, guardianship, curatorship, etc.) * Pregnant or breastfeeding woman * Subject participating in another research study that includes an exclusion period still ongoing at the time of pre-inclusion
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gastric cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU de la Guadeloupe
RECRUITINGPointe-à-Pitre, 97159, Guadeloupe
-
Cabinet Galeries de Houelbourg
RECRUITINGBaie-Mahault, 97122, Guadeloupe
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a personalized menu keep cancer patients stronger through chemotherapy?
- Nerve-Block procedure tested against severe pancreatic and stomach cancer pain
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- Can a direct hit to tumors make immunotherapy work better?
- New antibody aims to preserve immune checkpoint while fighting cancer
- Engineered immune cells target two markers on Hard-to-Treat tumors